# Development of Monoclonal Antibody Therapeutics for Anthrax

> **NIH NIH N01** · EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR · 2021 · $1,448,422

## Abstract

This contract supports the advanced development of a therapeutic for the treatment of anthrax. The scope of work for this contract includes preclinical and clinical development activities that fall into the following areas: IND-enabling activities; manufacturing activities; animal study activities; and BLA-enabling activities.

## Key facts

- **NIH application ID:** 10428336
- **Project number:** 272200800040C-P00005-9999-1
- **Recipient organization:** EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
- **Principal Investigator:** Virginia G. Johnson
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,448,422
- **Award type:** —
- **Project period:** 2008-09-01 → 2012-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10428336

## Citation

> US National Institutes of Health, RePORTER application 10428336, Development of Monoclonal Antibody Therapeutics for Anthrax (272200800040C-P00005-9999-1). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/10428336. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*